Eli Lilly & Co. (LLY) Reports In-Line Q3 EPS; Narrows FY11 EPS Outlook
Eli Lilly & Co. (NYSE: LLY) reported Q3 EPS of $1.13, in-line with the analyst estimate of $1.13. Revenue for the quarter came in at $0 versus the consensus estimate of $6.06 billion.
Eli Lilly & Co. sees FY2011 EPS of $4.30-$4.35, versus prior guidance of $4.25-$4.35 and the consensus of $4.33.
Eli Lilly & Co. sees FY2011 EPS of $4.30-$4.35, versus prior guidance of $4.25-$4.35 and the consensus of $4.33.